Shares of Acceleron Pharma (NASDAQ: XLRN) shot up significantly in after-hours trading on Monday when the company announced positive results for its drug to treat pulmonary arterial hypertension (PAH). A phase 2 clinical trial of Acceleron's drug candidate, sotatercept, met both the primary and secondary endpoints of the trial.
More specifically, the study in question found that there was a significant reduction in pulmonary vascular resistance, the amount of blood pressure in the arteries that provide blood to the lungs, in comparison to the placebo.
Image source: Getty Images.